BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27734526)

  • 1. Human myeloid inhibitory C-lectin: a highly specific and stable acute myeloid leukemia marker.
    Eissa DS; Kandeel EZ; Ghareeb M
    Hematol Oncol; 2017 Dec; 35(4):814-820. PubMed ID: 27734526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.
    Larsen HØ; Roug AS; Just T; Brown GD; Hokland P
    Cytometry B Clin Cytom; 2012 Jan; 82(1):3-8. PubMed ID: 22173921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
    Zhao F; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
    Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
    van Rhenen A; van Dongen GA; Kelder A; Rombouts EJ; Feller N; Moshaver B; Stigter-van Walsum M; Zweegman S; Ossenkoppele GJ; Jan Schuurhuis G
    Blood; 2007 Oct; 110(7):2659-66. PubMed ID: 17609428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
    Bakker AB; van den Oudenrijn S; Bakker AQ; Feller N; van Meijer M; Bia JA; Jongeneelen MA; Visser TJ; Bijl N; Geuijen CA; Marissen WE; Radosevic K; Throsby M; Schuurhuis GJ; Ossenkoppele GJ; de Kruif J; Goudsmit J; Kruisbeek AM
    Cancer Res; 2004 Nov; 64(22):8443-50. PubMed ID: 15548716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
    Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
    Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
    Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of minimal residual disease in acute myeloid leukemia.
    Gerhartz HH; Schmetzer H
    Leukemia; 1990 Jul; 4(7):508-16. PubMed ID: 1695705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34
    Wang YY; Chen WL; Weng XQ; Sheng Y; Wu J; Hao J; Liu ZY; Zhu YM; Chen B; Xiong SM; Chen Y; Chen QS; Sun HP; Li JM; Wang J
    Stem Cells Dev; 2017 Oct; 26(20):1460-1467. PubMed ID: 28810819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
    Herborg LL; Nederby L; Hasselbalch HC; Aggerholm A; Roug AS
    Int J Lab Hematol; 2018 Jun; 40(3):320-325. PubMed ID: 29427319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Distribution of antigenic aberration in the bone marrow of acute leukemia in complete remission].
    Shin S; Kahng J; Kim M; Lim J; Kim Y; Han K
    Korean J Lab Med; 2008 Feb; 28(1):1-7. PubMed ID: 18309249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
    Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
    Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunophenotyping of 106 adult patients with acute leukemia by flow cytometry].
    Xu B; Hu C; Miao XD; Wu YH; Yi ZS; Yang Y; Meng FY; Feng R; Liu QF; Liu XL; Zheng WY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Oct; 23(10):1043-6. PubMed ID: 14559689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
    Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
    Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.